 Home > Active Ingredient News > Antitumor Therapy > Eur J Cancer: Long-term efficacy of crizotinib in the treatment of advanced or metastatic inflammatory myofibroblastoma

Eur J Cancer: Long-term efficacy of crizotinib in the treatment of advanced or metastatic inflammatory myofibroblastoma

 Last Update: 2021-08-27
 Source: Internet
 Author: User

Tags

lag 3 inhibitor

iodine test results

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Inflammatory myofibroblastoma (IMT) is an extremely rare mesenchymal tumor that mainly occurs in children and adolescents

Inflammatory myofibroblastoma (IMT) Inflammatory myofibroblastoma (IMT) in children

Crizotinib is a small molecule tyrosine kinase inhibitor that targets ALK, MET, ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) and Recepteur d'Origine Nantais (RON)

G azole erlotinib (Crizotinib) is a small molecule tyrosine kinase inhibitors targeting ALK, MET, ROS proto-oncogene receptor tyrosine kinase (ROSl) and Recepteur d'Origine Nantais (RON) g oxazole Crizotinib is a small molecule tyrosine kinase inhibitor that targets ALK, MET, ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) and Recepteur d'Origine Nantais (RON)

The CREATE trial is a prospective, multicenter, non-randomized, open-label Phase 2 basket trial that evaluates the activity and safety of crizotinib for different types of cancer, including with or without anaplastic lymphoma Advanced inflammatory myofibroblastoma with kinase (ALK) rearrangement

Lymphoma

The test patients were patients with advanced/metastatic IMT who could not be cured by surgery, radiotherapy or systemic therapy

immunity

Progression-free survival

As of January 28, 2021, the researchers conducted a final analysis of the trial

The median follow-up was 50 months, 5 patients were still receiving crizotinib for a median follow-up of 50 months, and 5 patients were still receiving crizotinib for treatment of ALK-positive and ALK-negative patients.

Overall survival rate

In summary, the latest analysis results confirmed the results of previous studies, that is, crizotinib has a good treatment effect and lasting time for patients with locally advanced or metastatic ALK-positive IMT

Crizotinib is effective in treating patients with locally advanced or metastatic ALK-positive IMT and lasts for a long time

Original source:

Schöffski Patrick,Kubickova Michaela,Wozniak Agnieszka et al.

Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE https://doi.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.